Authors
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Latest:
The Benefits of Enhancing Adverse Event Intake With Case Collection SystemsAutomated risk management and improved regulatory compliance among opportunities offered by case collection.
Latest:
COVID and AMR: Crisis Reframes Antibiotics FightThe redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.
Latest:
Learning and Development Is the Key to Compliance in Life SciencesEmployees must be able to retain information and remain engaged to keep pace with highly regulated industry.
Latest:
The JAKs Journey Offers Valuable Lessons for InnovatorsOpportunity remains despite regulatory and access obstacles.
Latest:
Startup Launch Guide: Avoiding 10 Common Pain PointsWith opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Latest:
Why Pharma Must Invest in Key Account Management CapabilitiesThe emergence of organized customers demands investment in advanced solutions and next-generation key account management.
Latest:
The New Era of Purpose-Led Leadership in PharmaAcross all pharma companies' activities, the COVID-19 crisis has reinforced the need for pharma leaders to commit to, communicate, and exemplify the purpose that is at the center of their strategies and organizations.
Latest:
Navigating the Complexities of Patient Screening: Streamlining the Process for Accelerated Clinical TrialsDiscover how streamlining patient screening can help accelerate clinical trials. Simplifying and improving the patient journey and optimized screening processes can help improve clinical trial efficiency and stakeholder experience.
Latest:
Reimbursement Benchmark Share: An Objective Measure of the Impact of Product Reimbursement on Sales PerformanceKnowing that product reimbursement affects performance and varies by geography, this article proposes the use of Reimbursement Benchmark Share (RBS) to quantify the influence of reimbursement on a product’s performance.
Latest:
A Pricing Revolution: The State OffensiveThe second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Latest:
A Roadmap to Pharma ResilienceTo safeguard patient access to life-saving medications, pharma companies must prioritize building robust resilience strategies that encompass IT systems, inventory management, risk mitigation, and regulatory compliance.
Latest:
Reaching the Healthcare Professional After COVID-19Join Pharmaceutical Executive® for an information-packed virtual conference that provides valuable advice to bolster and transform the way you reach HCPs in this time of evolution. Live: Thursday, Aug. 13, 2020 at 8:15AM EDT. On demand available after airing until Aug. 13, 2021.
Latest:
The data you’re missingLatest:
The Personalized Patient Journey: A New Standard of Patient CentricityWebinar Date/Time: Wed, Apr 12, 2023 1:00 PM EDT
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
Navigating the CBD Research Landscape: Unveiling Best Practices in the Post-MMCREA EraAlthough research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
Latest:
Making the Most of the Rising Biopharma M&AsBiopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
Latest:
FDA Offers GDUFA III InsightThe Generic Drug User Fee Amendments, designed to facilitate the delivery of safe and effective generic drugs to the public and improve the predictability of the ANDA assessment process, has undergone changes that will impact the pre-ANDA and ANDA approval process—and ultimately the path for generic drugs to approval.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Gene Therapy on the Verge of Taking its Next Evolutionary StepThe shift from (ultra) rare to prevalent diseases calls for new vector manufacturing technologies
Latest:
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A RaceBig pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
Latest:
How Pharma is Reinventing Patient EngagementTuesday, October 12, 2021 at 1pm EDT | 10am PDT | 6pm BST We’re at a tipping point: patient engagement is now a key area of focus, and life sciences companies will be able to differentiate by shifting away from traditional models and embracing platforms that uniquely combine high tech with high touch. Join Andrea Heslin Smiley, President and CEO of VMS BioMarketing, the leading provider of patient adherence solutions, for a discussion on how the industry is rapidly transforming how it engages with its end customers.
Latest:
The Global Vaccine R&D Pipeline and Delivery ImplicationsThe current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
